India's primary market is set for a busy week ahead, with 20 initial public offerings due to open across the mainboard and SME segments, spanning fresh issues as well as new listings.


Among the mainboard names, pharmaceutical and specialty manufacturing companies are drawing the sharpest attention in the grey market. According to industry data tracked ahead of the issues, Tempsens Instruments — a diversified provider of temperature-sensing solutions, electrical heating systems and specialised cables used across power, steel, oil & gas, pharmaceuticals, aerospace and defence applications — has seen its unofficial grey market premium (GMP) imply listing gains of over 100%. Symbiotec Pharmalab, a research-led pharmaceutical and biotechnology company with a sizeable global share in corticosteroid and steroidal-hormone APIs, has also seen strong grey market interest, alongside Lumino Industries and Kwick Forensic Solutions, both commanding elevated premiums ahead of their respective openings.


Symbiotec Pharmalab's issue itself is one of the larger offerings in the mix, structured as a combination of a fresh issue and a sizeable offer for sale, with the company reporting a rise in both revenue and profit in its most recent fiscal year. Other mainboard names in the week's line-up include Augmont Enterprises, Skyways Air Services, Hy-Tech Engineers, Sunshine Pictures, Gaja Alternative Asset Management, Lalithaa Jewellery Mart, Shankesh Jewellers, Horizon Industrial Parks and Rays of Belief, while the SME segment sees issues from names such as Sumax Engineering, Annu Projects, Dhanwel Hybrid Seeds and Mopshop Distribution, among others.


It is worth noting that GMP is an unofficial, informal indicator quoted in the grey market ahead of listing, and it tends to fluctuate through the subscription period based on demand, broader market sentiment and subscription trends. It is not a regulated or guaranteed measure of listing-day performance, and final listing gains — if any — are determined only once shares are formally listed and traded on the exchanges.


As with any week carrying a high volume of primary market activity, investors are likely to track subscription numbers, anchor investor allocations and overall market conditions closely before these issues move toward listing.


Key Highlights

• 20 IPOs — across mainboard and SME platforms — are scheduled to open for subscription next week
  
  

• Tempsens Instruments, Symbiotec Pharmalab, Lumino Industries and Kwick Forensic Solutions are seeing the highest grey market premiums among the lot
  
  

• Symbiotec Pharmalab's issue combines a fresh issue with a large offer for sale, and the company has reported improved revenue and profit in its latest fiscal year
  
  

• Other mainboard issues in the week include Augmont Enterprises, Skyways Air Services, Hy-Tech Engineers, Sunshine Pictures and Gaja Alternative Asset Management
  
  

• GMP remains an unofficial, non-regulated indicator that can change significantly before listing
  
  

• Final listing outcomes will depend on subscription levels, allotment, and market conditions at the time of listing
  
  

Conclusion

The coming week's IPO calendar reflects continued momentum in India's primary markets, with a broad mix of pharmaceutical, industrial, and consumer-facing companies tapping public capital across both the mainboard and SME segments. While grey market premiums are pointing to strong investor interest in a handful of these issues, they remain an informal gauge rather than a confirmed outcome. As always, actual listing performance will hinge on final subscription numbers, allotment patterns, and prevailing market sentiment closer to each listing date.


Disclaimer

This article is intended solely for informational and educational purposes and should not be interpreted as financial, investment, legal, tax, regulatory, or professional advice of any kind.
The content is based on publicly available information, official statements, government announcements, and media reports available at the time of publication. FinMen Advisors is not affiliated with, endorsed by, or officially associated with the companies mentioned, SEBI, or any other organizations referenced in this article unless expressly stated otherwise.
Readers are advised to independently verify information through official government notifications, regulatory disclosures, institutional filings, and professional advisors before making any business, financial, investment, or regulatory decisions. Any forward-looking observations, market interpretations, or industry perspectives mentioned herein are subject to change based on policy developments, regulatory updates, and market conditions.


Source: The Economic Times